Has Michael Papagikos, MD received payments from drug or device companies?

Yes. Drug and device makers reported $50,743 in general payments to Michael Papagikos, MD across 72 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Papagikos, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Papagikos, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Papagikos, MD

Radiation Oncology · Wilmington, NCNPI 1831118660

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (51.8%), ownership interests and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 85.8% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2020 at $19,199 and has fallen 97.7% since, to $433 in 2025. Among radiation oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$50,743in general payments, 2019–2025

Across 72 payments — averaging $704.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$44K
Varian Medical Systems, Inc.$3K
Augmenix, Inc.$2K
Johnson & Johnson$227
Siemens Medical Solutions USA, Inc.$222
Progenics Pharmaceuticals, Inc.$171
plus $1K from 17 others

What the payments were for

Consulting fees$2,3355%
Speaking & faculty fees$2,0004%
Travel & lodging$9862%
Food & beverage$2,0404%
Ownership interest$17,07534%
Other$26,30852%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	8	$43,526
Varian Medical Systems, Inc.	8	$3,153
Augmenix, Inc.	1	$2,335
Johnson & Johnson	7	$227
Siemens Medical Solutions USA, Inc.	4	$222
Progenics Pharmaceuticals, Inc.	4	$171
Bayer	9	$167
Pfizer	7	$166
Monteris Medical Corporation	1	$124
Merck	4	$109
Astellas Pharma US Inc	3	$96
AstraZeneca	1	$88
Novartis	3	$74
Myovant Sciences Inc.	1	$65
Exelixis Inc.	2	$39
AVEO Pharmaceuticals, Inc.	1	$36
Eisai Inc.	2	$32
Teleflex LLC	1	$24
Myriad Genetic Laboratories, Inc.	1	$21
Brainlab, Inc.	1	$19
Novocure Inc.	1	$17
Cardinal Health 414 LLC	1	$17
Blue Earth Diagnostics	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,743 in reported general payments places this provider in the 95th percentile of 199 radiation oncology providers in North Carolina.

See all radiation oncology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$271,277

Medicare patients

428

Services billed

2,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	151	$1,666
Bicalutamide	11	$147
Ondansetron Hcl	11	$57

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Wilmington

Tiffany MorganWilmington$2K
Rex KiteleyWilmington$2K
Mustafa AbugideiriWilmington$1K
Andrew WangChapel Hill$118K
Volker StieberWinston Salem$99K
Lewis SulmanDurham$54K
William LeeDurham$37K
Matthew ManningGreensboro$33K
Michael ChanWinston Salem$32K
John KirkpatrickDurham$29K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →